Medical Condition News

RSS

OPKO Health, Scripps Research partner to commercialize Parkinson's disease compound, SR 3306

The Scripps Research Institute and OPKO Health, Inc. today announced a global agreement for the development and commercialization of SR 3306, a novel compound discovered by scientists from the Florida campus of The Scripps Research Institute that blocks the destruction of brains cells in animal models of Parkinson's disease.

12 Mar 2012

Insulin and nutrition keep blood stem cells from differentiating into mature blood cells

UCLA stem cell researchers have shown that insulin and nutrition keep blood stem cells from differentiating into mature blood cells in Drosophila, the common fruit fly, a finding that has implications for studying inflammatory response and blood development in response to dietary changes in humans.

12 Mar 2012

Salk scientists' discovery explains how a class of chemotherapy drugs works

The well-being of living cells requires specialized squads of proteins that maintain order. Degraders chew up worn-out proteins, recyclers wrap up damaged organelles, and-most importantly-DNA repair crews restitch anything that resembles a broken chromosome. If repair is impossible, the crew foreman calls in executioners to annihilate a cell. As unsavory as this last bunch sounds, failure to summon them is one aspect of what makes a cancer cell a cancer cell.

12 Mar 2012

Allon advances into second phase of work in preclinical PD model

Allon Therapeutics Inc. announced today the completion of its first phase of work in a preclinical Parkinson's disease model and advancement into the second phase of work. Both phases are funded by The Michael J. Fox Foundation for Parkinson's Research and carried out by Prof. Marie-Francoise Chesselet's lab at the University of California Los Angeles.

12 Mar 2012

InflammaGen Therapeutics initiates Shok-Pak Phase 2 pilot study

InflammaGen Therapeutics, a development-stage, critical care company initially focused on the diagnosis, treatment and prevention of multi-organ failure (MOF), announced today that the Company has initiated a 200-patient Phase 2 pilot study to examine the efficacy and safety of InflammaGen Shok-Pak as a potential treatment for critically ill patients in the Intensive Care Unit.

12 Mar 2012

Connect during MS Awareness Week

Multiple sclerosis is a life altering disease that affects each person in a unique and different way. MS destroys connections, divides minds from bodies, pulls people from their lives and away from one another. Therefore, it's only fitting that connections would be its greatest enemy.

12 Mar 2012

FDA clears Aradigm IND for Pulmaquin Phase 3 clinical trial in non-cystic fibrosis BE

Aradigm Corporation today announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis (BE) has been cleared by the U.S. Food and Drug Administration.

12 Mar 2012

Two scientists receive The Brain Prize 2012 for pioneering work on hearing and deafness

The Grete Lundbeck European Brain Research Foundation announced today that The Brain Prize 2012 is jointly awarded to Christine Petit and Karen Steel.

12 Mar 2012

Interventional Spine's PerX360 System to be presented at ISASS annual meeting

Interventional Spine, Inc. today announced that Dr. Rudolf Morgenstern, Director and Chief Surgeon of the Morgenstern Institute for Endoscopic Spine Surgery at Centro Medico Teknon in Barcelona, and Dr. David Greenwald from Flagler Brain and Spine Institute of St. Augustine, Florida will present the PerX360 System at the International Society for the Advancement of Spine Surgery (ISASS) Annual Meeting in Barcelona, Spain.

12 Mar 2012

InflammaGen to initiate Phase 2 study of new drug/delivery platform for shock

A 200-patient Phase 2 clinical pilot study will be initiated this month to test the efficacy and safety of a new use, and method of administering, an enzyme inhibitor for critically ill patients developed by University of California, San Diego Bioengineering Professor Geert Schmid-Sch-nbein. Conditions expected to qualify for the study include new-onset sepsis and septic shock, post-operative complications, and new-onset gastrointestinal bleeding.

12 Mar 2012

UHC retires negative coverage policy effective April 1, 2012

Aerocrine AB announces that United Healthcare has retired its negative coverage policy effective April 1, 2012.

12 Mar 2012

Gastrointestinal progenitor cells could be coaxed into making insulin

A study by Columbia researchers suggests that cells in the patient's intestine could be coaxed into making insulin, circumventing the need for a stem cell transplant. Until now, stem cell transplants have been seen by many researchers as the ideal way to replace cells lost in type I diabetes and to free patients from insulin injections.

12 Mar 2012

Many children with life limiting conditions have been underestimated

The number of children with conditions such as muscular dystrophy, neurodegenerative disorders or severe cerebral palsy who are surviving into adulthood has been underestimated, a new study shows.

12 Mar 2012

Johns Hopkins epidemiologist named Distinguished Service Professor of Medicine

Frederick L. Brancati, M.D., M.H.S., professor of medicine and epidemiology at the Johns Hopkins University School of Medicine and director of Hopkins' division of general internal medicine, was named Distinguished Service Professor of Medicine by the Johns Hopkins University Board of Trustees.

12 Mar 2012

Researchers produce extensive catalog of genes expressed in human islets

A new JDRF-funded study shows that many of the genes known to play a role in type 1 diabetes (T1D) are expressed in pancreatic beta cells, suggesting that the cell responsible for producing insulin may be playing a part in its own destruction to lead to T1D.

12 Mar 2012

FDA denies AstraZeneca Citizen Petitions on SEROQUEL labeling

AstraZeneca today announced that on March 7, 2012, the Food and Drug Administration denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.

12 Mar 2012

HSS summit: Current classification system for osteoarthritis is inadequate

A recent summit that brought together international multidisciplinary experts has provided a foundation for addressing what is the leading cause of disability in the United States: osteoarthritis.

12 Mar 2012

DeSyRe develops new design techniques for future Systems-on-Chips

For pacemakers and other implantable medical devices there are three key factors: extreme reliability, small size, and long longevity. In the EU project DeSyRe, researchers tackle these issues with a new approach: building a reliable system on unreliable components. Ioannis Sourdis, project leader, today explains the DeSyRe's approach in a tutorial on "Hardware and software design and verification for safety critical electronic systems" during the DATE 2012 conference in Dresden.

12 Mar 2012

PXR protein can protect against cardiovascular disease

Researchers from Queen Mary, University of London and the University of Surrey have found a protein inside blood vessels with an ability to protect the body from substances which cause cardiovascular disease.

12 Mar 2012

TGen to present new research about multiple myeloma at AzMN conference

The Translational Genomics Research Institute (TGen) will present new research about the blood-cell cancer known as multiple myeloma at a free public conference hosted by the Arizona Myeloma Network.

12 Mar 2012